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Abstract
Herpesvirus entry into cells begins when viral membrane glycoproteins bind to cellular
receptors. This receptor binding elicits a cascade of interactions among conserved viral
membrane glycoproteins that triggers virus-cell membrane fusion. Details of the viral protein
interactions are not well understood because they are likely transient and/or low affinity.
Proximity biotinylation (ProB) is a promising technique for dissecting the glycoprotein
interactions required for entry. In ProB, one protein is linked to a bacterial biotin ligase and a
second protein is linked to a target 15 amino acid acceptor peptide (AP). If the proteins interact,
the ligase on the first protein catalyzes site-specific biotinylation of the AP on the second protein.
Evidence of interaction can be detected by western blotting with streptavidin to visualize
biotinylated proteins. Labeling is covalent and occurs within live cells, thus weak and transient
interactions can be detected. The short length of AP reduces the risk of altering the native
conformation of the glycoproteins.
Sensitivity and specificity are concerns for all interaction assays. To establish optimal
conditions for ProB, the biotin ligase and AP were linked to herpes simplex virus gD and Epstein
Barr virus gB. These oligomeric herpesvirus proteins do not interact functionally and assaying
for a heterotypic interaction between them serves as a negative control to demonstrate specificity
of the ProB assay. Homotypic interactions between their monomers serve as a positive control to
demonstrate sensitivity. The positive controls show strong biotinylation, indicating that
proximity of viral membrane proteins can be detected. Unexpectedly, the negative controls also
showed biotinylation, albeit at a lower level. These results demonstrate the special circumstances
that must be considered when examining interactions among proteins that are constrained within
the two-dimensional boundaries of a membrane. The lab is currently investigating ways to limit
the heterotypic interaction and designing constructs to further test ProB validity for membranerestricted protein interactions.
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Abbreviations

CHO

Chinese hamster ovary

FBS

Fetal bovine serum

Ham’s

Ham’s F12 nutrient mixture

ProB

Proximity Biotinylation

HSV

Herpes simplex virus

EBV

Epstein Barr virus

BSA

Bovine serum albumin

PBS

Phosphate buffered saline

PBS+

Phosphate buffered saline with magnesium chloride and calcium chloride

PBS-T

Phosphate buffered saline with Tween-20

HRP

Horseradish peroxidase

RIPA

Radioimmunoprecipitation assay buffer

SDS

Sodium dodecyl sulfate

BME

Beta-mercaptoethanol

PCR

Polymerase Chain Reaction

BiFC

Bimolecular Fluorescence Complementation

cELISA

Cell-based enzyme-linked immunosorbent assay

IP

Immunoprecipitation
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I. Review of Literature

A. The Herpesviridae Family
Herpesviruses cause a lifelong infection of a large variety of animal hosts, and the
average person carries multiple herpesviruses (36, 70). Herpesviruses are double-stranded linear
DNA viruses with genomes ranging from 120 to 230 kb in length (60). The herpesvirus genome
is encased in a proteinaceous capsid that is enclosed within a lipid envelope (60). Embedded in
this envelope are approximately a dozen glycoproteins that are responsible for interactions with
the host cell (60). The space between the capsid and the envelope contains proteins called
tegument that are essential to the establishment of infection after entry into the cell, for example
transcription factors (60).
There are eight human herpesviruses that cause a variety of diseases, ranging from cold
sores to cancers. The Herpesviridae family is divided into three subfamilies—alpha, beta, and
gammaherpesviruses. This project focuses on the human alphaherpesvirus herpes simplex virus 1
and the human gammaherpesvirus Epstein-Barr virus. Alphaherpesviruses are characterized by
their ability to establish lifelong latent infections in the peripheral nervous system of a host. An
infection is defined as latent when the virus is present but dormant and producing no overt
symptoms. Alphaherpesviruses have a short growth cycle and rapid spread. The human viruses
within the alphaherpesvirus subfamily include herpes simplex virus 1 (HSV1), herpes simplex
virus 2 (HSV2), and varicella-zoster virus (VZV), the causative agents of cold sores, genital
lesions, and chickenpox respectively. Gammaherpesviruses are characterized by the viral growth
in epithelial and B- or T- lymphocytes. The human viruses within the gammaherpesvirus class are
Epstein-Barr virus (EBV) (51) and human herpesvirus 8 (HHV-8). EBV causes infectious
mononucleosis, Burkitt’s lymphoma, and nasopharyngeal carcinoma, where as HHV-8 causes
Kaposi’s sarcoma.

	
  

1

	
  
Although the typical course of herpesvirus infection results in modest symptoms, serious
and potentially life-threatening complications can occur. Gammaherpesvirus infections may be
asymptomatic, but they may also result in the cancers mentioned above. Complications from
alphaherpesvirus infection include herpes encephalitis, herpes meningitis, ocular herpes,
gingivastomatitis, shingles, and postherpetic neuralgia. The severity of these complications
highlights the importance of understanding all aspects of the virus life cycle, including virus entry
into cells, replication and assembly within cells, release from cells, spread through tissues and
interactions with the immune system. This thesis will focus on HSV1 and the interactions of
envelope glycoproteins with the host cell during entry, the first step of viral infection. The entry
step is an attractive target for antiviral intervention because if the virus is prevented from entering
the cell, the infection is never established.
Herpesviruses use a conserved set of machinery to enter into cells. The glycoproteins for
HSV1 and HSV2 are so similar that they are functionally interchangeable. Learning about HSV1
is directly applicable to HSV2 and other enveloped viruses, such as paraymyxoviruses, which
also encode for a receptor binding and fusion of separate glycoproteins.

B. Epidemiology
HSV1 and HSV2 cause genital herpes, however HSV2 is the most common cause. In
2003, more than 500 million people worldwide were infected with HSV2 and more women than
men were infected (44). In the 1970s and 1980s, over 30% of women diagnosed with genital
herpes were infected with HSV1 (69). HSV1 is now responsible for 40% of new cases of genital
herpes (17). In a study tracking primary HSV infection in women for 20 months, 3.7% of the
women (127 out of 3438 participants) were infected with HSV1 while only 1.6% were infected
with HSV2 (9). Infection rates differ greatly between racial groups. From the study tracking
women for 20 months, HSV2 infections were found to vary significantly among racial groups:
74% black, 40% Hispanic, and 23% white (9). Other studies have found similar results. HSV2
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seroprevalence was found in 21.9% of the overall population (22). The individuals with HSV2
infections also varied among racial groups: 45.9% black, 22.3% Hispanic, and 17.6% white (22).
Overall, HSV1 and HSV2 are increasing in prevalence.

C. HSV1 Entry Glycoproteins
HSV may enter cells through two pathways, depending on cell type. HSV1 virions are
able to infect lymphocytes, epithelial cells, fibroblasts, and neurons. There are two entry
pathways both requiring viral glycoproteins to induce fusion: fusion can occur at the cell surface
at a neutral pH or in the endosome in a low pH-dependent manner. (48, 52). Many aspects of
herpes simplex virus entry into cells are understood, but the overall sequence of events and
interactions among entry proteins is disputed. For HSV1, a small set of glycoproteins in the viral
membrane envelope (gB, gD, gH, and gL) are both necessary and sufficient for fusion of the virus
with the host cell (56, 68) (Fig.1). Glycoproteins gD, gB, gH, and gL are the minimum viral
requirement needed for entry into the cell and viruses deleted for any of these glycoproteins fail
to enter cells (56, 68). The nature of the interaction between these proteins has yet to be defined,
including the order of interactions and the site of interactions.
In the first step of entry, the virus tethers to heparan sulfate proteoglycans on the host cell
surface via the viral glycoproteins gB and gC. Although the gB and gC interaction with heparan
sulfate enhance the efficiency of virus entry, these interactions are not required for entry (30, 41).
Removal of heparan sulfate binding capacity does not inactivate the virus. Binding to heparan
sulfate does not trigger the conformational changes in the viral proteins that are required to cause
fusion of the viral envelope with the cellular membrane.
Fusion is triggered by the binding of gD to a specific cellular receptor(66). The two
widely studied receptors that bind to gD include nectin-1 and herpesvirus entry mediator
(HVEM). Nectin-1 is thought to be a critical herpesvirus receptor, and it is expressed on neurons;
neurons are a key cell type for HSV1 infection as this is the cell type in which HSV1 establishes
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Figure 1. Interactions that mediate HSV entry. HSV entry into a cell requires four essential
glycoproteins found on the viral envelope: gD, gH, gL, and gB. These glycoproteins both are necessary
and sufficient for the fusion of the viral lipid envelope with the cell membrane. In the current model,
virus entry is initiated when gD, which exists as a dimer, binds to a specific receptor on the membrane of
the host cell. The most common receptors are nectin-1 and herpes virus entry mediator (HVEM).
Receptor-binding results in conformational changes in gD that have been observed using
crystallography. Due to structural similarity between gB and other viral fusion proteins, gB is believed
to be responsible for physically inserting into the host cell membrane and then refolding to execute
membrane fusion. gH and gL form a heterodimer, and the role gH/gL is less clear. gH/gL and gD alone
are insufficient for fusion and gH/gL does not resemble any known fusion protein. Thus, gH/gL likely
plays a role in transmitting a signal to gB to trigger the fusion event. How gD interacts with gH/gL
and/or gB to trigger fusion of the virus with the target cell after receptor binding is poorly understood.
The interactions among the glycoproteins are hard to capture, presumably because they are either low
affinity or transient interactions.
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latency (38, 58). Transgenic mouse models of HSV1 infection have demonstrated that deletion of
nectin-1 greatly inhibits virus infection and spread through the host (35, 37, 65). The nectin
family of molecules function in intercellular adhesion. HVEM, formerly known as HveA, is a
member of the tumor necrosis factor receptor family and is expressed on a variety of tissues,
including immune cells (50). Transgenic mouse models of HSV1 infection have suggested that
HVEM is a dispensable receptor because HSV1 infection in the absence of HVEM proceeds at
near-wild type manner (35, 37, 65). The reason why HSV1 retains the ability to use HVEM as a
receptor is unclear. In fact, a point mutation in gD is sufficient to eliminate HVEM binding
without preventing nectin-1 usage (39). The retention of HVEM binding by gD suggests that
HVEM contributes to the virus life cycle in some manner, perhaps in an as-of-yet undefined
immune evasion strategy. A third receptor that gD can bind is a 3-O-sulfated heparan sulfate, a
type of heparan sulfate (61). The contribution of 3-O-sulfated heparan sulfate to HSV1 infection
of an animal remains unclear.
HSV1 gD has 369 amino acid residues and forms a dimer (39). gD is unique to
alphaherpesviruses and other families of herpesviruses use other receptor binding proteins. For
example, EBV uses the receptor binding protein, gp42 that communicates with gH/gL and gB for
entry into B cells. The crystal structure of gD has been determined alone and in complex with the
receptors HVEM or nectin-1 (11, 18, 39). Glycoprotein gD has no sequence homology to other
proteins, however it has a V-like immunoglobulin fold at its core from residues 56 to 184 (11).
Immunoglobulin-like folds are found on many proteins in the immune system and proteins
involved in cell-cell recognition and adhesion in nervous system. The residues on gD that bind
HVEM are located entirely on an N-terminal extension that is supported by the core of the gD
molecule (11). The binding site of nectin-1 is distinct from but overlaps with the binding site of
HVEM. Nectin-1 binds to residues within the gD core as well as residues near the gD N-terminus
(18). Specifically, the gD residue tyrosine 38 is critical for nectin-1 binding (18). The gD Cterminus is a flexible structural element that is able to interfere with receptor binding (39). It has
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been suggested that the C-terminus of gD normally occludes the receptor-binding site and that
upon receptor binding, this gD C-terminus is displaced. This movement of the gD C-terminus
may be the signal that triggers the next step of entry. The protein(s) that gD interacts with after
receptor binding has not been fully established.
gB is a 904 residue protein that is conserved among all herpesviruses and exists as a
trimer (29). The crystal structure of HSV1 gB revealed a striking structural similarity to a
rhabdovirus fusion protein, despite the fact that gB has no sequence homology to this protein (29,
59). The ectodomain of EBV gB has also been characterized (7). This structural similarity to a
known fusion protein strongly suggests that gB is also a fusion protein. Fusion proteins are
responsible for physically fusing the viral membrane with the cellular membrane. They are
expressed initially in a prefusion conformation. Upon triggering, they insert hydrophobic
residues (called fusion loops or fusion peptides) into a target membrane and then refold into a
postfusion conformation, dragging the viral membrane and cellular membrane together to force
membrane fusion. The crystal structure of gB reveals putative fusion loops and these
hydrophobic loops are critical for fusion (29). gB represents a class III fusion protein,
characterized by the presence of fusion loops and a coiled-coil domain (16, 29). Mutations in a Cterminal region of the gB ectodomain that contacts the coiled-coil domain inhibit the ability of gB
to execute fusion, suggesting that residues in this C-terminal region may provide a driving force
for gB refolding into its postfusion conformation (16). gB is reported to be to be required for
HSV1 nuclear egress, the process wherein the capsids leave the nucleus after being loaded with
genome. The requirement of gB for nuclear egress may indicate that gB mediates fusion of an
initial virion envelope (comprised of the inner nuclear membrane) with outer nuclear membrane.
When the fusion loops of gB were mutated, the virus was unable to exit the perinuclear space
(71). Unexpectedly, gB and gH were reported to have redundant functions in nuclear egress, a
redundancy that does not occur during virus entry (71).
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The glycoproteins gH and gL are found in a heterodimer (32). gL is required for correct
folding, surface expression, and function of gH, and thus the two proteins are treated as one
functional unit, referred to as gH/gL (63). Prior to the solution of the crystal structure of gB,
gH/gL was thought to be a viral fusion protein. This idea stemmed from four reports. First, as
mentioned above, gH was reported to function in nuclear egress. Second, some stretches in gH
resemble hydrophobic and helical peptides that are present in known fusion proteins (23, 26).
Third, gD and gH/gL were reported to be sufficient for hemifusion in the absence of gB (64).
Hemifusion is an intermediate step in fusion wherein the outer leaflets of the two lipid bilayers
mix prior to the formation of a fusion pore. Fourth, gH/gL from the alphaherpesvirus VZV was
reported to be sufficient alone for cell-to-cell fusion (19). The general consensus in the field now
is that gH/gL is not a fusion protein (13). More recent studies report that both VZV gH/gL and gB
are required for fusion (45) and that gH/gL is insufficient for hemifusion (34).
The crystal structure of the gH/gL complex from HSV2 were determined recently (13).
There are crystal structures of EBV gH/gL and a partial structure of pseudorabies gH as well (6,
46). The sequences of HSV1 gH and gL are highly homologous to those of HSV2 gH and gL, so
the structure of HSV1 gH/gL is likely very similar to that of HSV2 gH/gL. HSV2 gH/gL has a
boot shaped structure. The glycoprotein gH has three domains (H1-H3). H1 is an N-terminal
domain that binds to gL; H2 is a central helical domain; and H3 contains a C-terminal β-sandwich
domain (13). The H3 domain sequence is highly conserved among herpesviruses and may play a
functionally important role. gH is required for the proper folding of gL since gL does not have a
stable core itself. Glycoprotein gL has four cysteines that form two disulfide bonds that are
conserved among other herpesviruses (13). gH has been shown to bind αvβ3 intergrins molecules
at a Arg-Gly-Asp (RGD) motif (55). Other viruses use intergrins as entry receptors, including
HHV8. This may not be the case for HSV since mutations in the RGD motif did not limit
infection in vitro (55). Intergrin-gH interactions may play a role in entry in other cell types in
vivo. gH/gL is proposed to transmit activating signals to gB, allowing gB execute membrane
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fusion (63). The function of gH/gL is still unknown since it does not function as the fusion
protein yet is necessary for HSV fusion.

D. EBV entry glycoproteins
EBV and HSV1 share three conserved essential entry glycoproteins—gB, gH, and gL.
HSV1 requires gD to bind to a cellular receptor to trigger fusion; however, EBV does not encode
a gD. Entry of EBV, like HSV, is cell type dependent; EBV can infect B cells, epithelial cells,
and monocytes (43). Entry into B cells occurs through viral glycoproteins interacting with a
cellular receptor either on the cell surface or in the endosome in a pH-dependent fashion (14, 47).
For B cell entry, glycoprotein 42 (gp42) replaces the function of HSV1 gD and binds to the
cellular receptor human leukocyte antigen class II (HLA class II) (42). gp42 is cleaved near the
N-terminus but remains attached to the virion due to binding to gH/gL (57). Conformational
changes in gp42 and/or gH/gL trigger gB to insert fusion loops into the B cell. gB undergoes a
conformational change causing fusion between the viron membrane and B cell membrane.
EBV entry into epithelial cells occurs differently. gp42 is not required for epithelial cells
entry, and gp42 inhibits entry into epithelial cells. EBV entry into epithelial cells requires only
gH/gL and gB. gH/gL is responsible for attachment to the epithelial cells. Some evidence shows
that gH/gL binds to αν integrins on epithelial cells(49, 72, 73). After receptor-binding, gH/gL is
able to interact with gB, causing gB to insert its fusion loops into the epithelial cell membrane
(12). gB undergoes a conformational change causing fusion of the two membranes.
EBV has evolved a mechanism to alter tropism of the virus from epithelium to B cells
and back to epithelium in a host. The viruses made in B cells have low amount of gp42 since the
3-part complex (gHgLgp42) is degraded in the endoplasmic reticulum if the complex interacts
with HLA class II (10). The viruses made in epithelial cells have high amounts of gp42 since
these cells do not have MHC class II molecules (10). The virus from B cells is more infectious to
epithelial cells; while, the virus from epithelial cells is more infectious to B cells.
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E. Glycoprotein Interactions
The glycoproteins gD, gB, and gH/gL are required for HSV1 entry and their interactions
are an active area of research. Using chemical cross-linkers, heterodimers of gB-gC, gC-gD, and
gD-gB have been detected (27, 28). Co-immunoprecipitation of the glycoproteins is challenging
because the interactions are likely transient and/or low affinity and the proteins may disassociate
during a pull-down assay. The glycoproteins exist in native membrane-anchored states on the
virion envelope and the detergents required for a pull-down assay may perturb the normal
interactions. One research group has reported using a pull-down assay to detect all of the
glycoproteins interacting with all of the other glycoproteins (25).
Given the limitations of the pull-down assay, a new method emerged to study
glycoprotein interactions—bimolecular fluorescence complementation (BiFC). BiFC allows for
direct visualization of protein interactions in a living cell. One candidate protein is fused with the
N-terminal portion of a fluorescent protein and another candidate protein is fused with the Cterminal portion of the fluorescent protein. The interaction between two candidate proteins drives
the formation of a functional fluorescent complex as the two fragments of the fluorescent protein
are brought into proximity (31). Visualization of physical interactions is possible in the normal
environment of a living mammalian cell. BiFC has known complications. Use of a fluorescent
tag can drive proteins to the wrong cellular compartment or cause the proteins to misfold (67). In
addition, false positives are a concern. The two portions of the fluorescent protein have intrinsic
affinity for one another, and this affinity can contribute spuriously to interactions between
proteins (15, 31). The fluorescent halves do not come apart after interacting with one another.
False negatives are also possible since the fluorescent protein fragments can sterically block
protein-protein interactions (31). Another concern is that BiFC is characterized through
microscopy, which can be more subjective than western blotting.
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BiFC has been used to study glycoprotein interactions in HSV1. Initially, two research
groups using BiFC reported that gD is able to interact with gB in the absence of gH/gL (2). The
inverse was also true; gD was able to interact with gH/gL in absence of gB (2). Most notably,
gH/gL was able to interact with gB, but only in the presence of gD, suggesting that gD binding to
receptor triggered a gH/gL-gB interaction (2, 4). These BiFC studies supported a proposed model
in which gD binding to receptor causes a conformational change in gD that activates gH/gL to
interact with gB which then executes membrane fusion (3, 16) (Fig. 1).
This proposed model stands as the generally accepted model of herpesvirus entry
however further studies using BiFC have clouded the model. After further study, one of the
research groups above used BiFC to demonstrate that gB can bind to gH/gL in the absence of gD
(4, 5). Later studies used BiFC to probe the sites of glycoprotein interactions using mutant
glycoproteins and monoclonal antibodies that block virus entry (1). These studies found that
gH/gL failed to interact with a gB carrying mutations in its fusion loops. This result led the
researchers to propose that gB inserts its fusion loops into the host cell membrane prior to an
interaction with gH/gL, a suggestion that leaves the signal that triggers gB to insert its fusion
loops into the host cell membrane unaccounted for. In a study on paramyxoviruses, BiFC resulted
in fluorescence when the receptor-binding protein was co-expressed with its fusion protein but
also when it was co-expressed with unrelated BiFC labeled constructs, showing BiFC may be
driving the interactions (15). These conflicting results highlight concerns with the BiFC technique
and the leave questions regarding the sequence of interactions among HSV1 glycoproteins.

F. Proximity Biotinylation
With the false positive and false negative concerns of BIFC, the interactions between the
HSV1 proteins and the sequence of events are unclear. Another new technique, proximity
biotinylation, can be used to characterize the protein-protein interactions. Proximity biotinylation
uses an enzyme and substrate pair to detect candidate protein interactions. One candidate protein
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is tagged with the Escherichia coli biotin ligase enzyme (BirA), and another candidate protein is
tagged with a 15 amino acid acceptor peptide substrate (AP). If BirA and AP come into close
proximity, BirA will covalently ligate biotin to the AP (Fig. 2). The interaction can be observed
by microscopy using fluorescently labeled streptavidin or by western blot using streptavidin to
visualize the biotinylated proteins. Multiple versions of the AP target peptide with differing
affinities for BirA are available, and these options allow for optimization of signal over
background noise (21, 67).
Proximity biotinylation is a promising technique for many reasons. Labeling can be done
in live cells. Cells can be transfected with different combinations of viral glycoproteins in the
presence and absence of receptor. The interaction between biotin and streptavidin is high affinity
and highly sensitive. Endogenous mammalian biotin ligase does not recognize the AP target
peptide. A low false positive rate across a wide range of protein expression levels has been
reported (21). Since the AP is only 15 amino acids compared to the large BiFC fluorescent tags, it
is less likely to alter the glycoprotein function. BirA and the AP are able to move apart after an
interaction so proteins are free to move in the membrane, making it an ideal technique for
transmembrane protein interactions. Another advantage to ProB is that the biotin is covalently
linked to the AP tag permanently tagging the protein with biotin. Since detection of biotinylated
proteins is done on the cell lysates through western blotting, the interaction between proteins can
be clearly identified. ProB has the potential to be a useful protein-protein interaction technique
without the need for microscopy, the ability to use western blotting, no time delay, or the use of a
fluorophore. This technique is worth optimizing to use for transient, transmembrane interactions.
ProB has potential to characterize herpesvirus glycoproteins interactions due to these lucrative
advantages.
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G. Project Overview
The goal of this thesis project is to optimize a proximity biotinylation assay and
determine whether it can be used to study the herpesvirus entry glycoprotein interactions. One
aim is to determine if biotinylation is detectable through the use of positive and negative controls.
The other aim is to determine the optimal conditions of ProB assay. Interactions between the
subunits of known oligomers serve as the positive controls. Coexpression of HSV gD constructs
linked to BirA and AP is expected to result in biotinylation because gD oligomerizes (homotypic
interaction). Similarly, coexpression of EBV gB linked to BirA and APm serves as a positive
control (homotypic interaction). Coexpression of proteins that are not expected to interact serve
as negative controls (heterotypic interactions). HSV gD and EBV gB do not functionally interact
and thus coexpression of HSV gD and EBV gB constructs linked to BirA or AP is not expected to
result in biotinylation. By establishing positive and negative controls, ProB could be used to
detect the glycoprotein interactions between HSV gB, gD, and gH/gL before and after gD binds a
cellular receptor, and before and after fusion occurs.
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Figure 2. Proximity biotinylation. Proximity biotinylation (ProB) is a technique wherein an
enzyme and substrate pair is used to determine if an interaction occurs. One target protein is
tagged with Escherichia coli biotin ligase enzyme (BirA) and the other protein is tagged with its
substrate, a 15 amino acid acceptor peptide (AP). If an interaction occurs between the two target
proteins, BirA will covalently ligate biotin to the AP. Streptavidin, which has a high affinity for
biotin, can then be used to visualize the biotinylated target proteins by western blot or
fluorescence microscopy.
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II. Methods

A. Cells, antibodies, and plasmids. Chinese hamster ovary (CHO-K1) cells lack HSV-1
receptors and were grown in Ham’s F-12 medium supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin (58) at 37°C in 5% CO2. CHO-nectin1 is a cell line derived
from CHO-K1 cells that expresses the HSV1 receptor nectin-1. They were grown in Ham’s F-12
medium supplemented with 10% FBS, 1% PS, and 250 µg/mL G418. Trypsin-EDTA was used
to detach these adherent cells. The antibodies used include anti-HSV1 gD polyclonal antibody
(PAb) R7 (33) anti-HSV1 gD 340-356 PAb (20), anti-EBV gB monoclonal antibody (MAb)
CL55 (73) anti-EBV gB PAb (8), anti-hemagglutinin (HA) tag MAb 12CA5 (53), anti-FLAG
M2 MAb (Sigma F9291), horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG PAb
(Pierce), and HRP-conjugated goat anti-rabbit IgG PAb HRP (Pierce). HRP-conjugated
streptavidin (Pierce) was used to detect biotin. Wildtype HSV glycoproteins were expressed using
the pCAGGS vector (54). HSV1 gD-BirA, gD-AP, gD-APm EBV gB wildtype (24), EBV gB767
(24), EBV gB816 (24), gB-BirA, gB-AP, gB-APm were expressed using the pSG5 vector
(Agilent). For the syncytium formation assay the following plasmids were used: pPEP98
(pCAGGS-HSV1 gB), pPEP99 (pCAGGS-HSV1 gD), pPEP100 (pCAGGS-HSV1 gH), and
pPEP101 (pCAGGS-HSV1 gL).

B. Transfection. CHO-K1 cells were transfected in Opti-MEM (Gibco) medium using
Lipofectamine 2000 (Invitrogen) according to the manufactures directions. Cells were grown in a
24 well dish overnight and transfected with various combinations of expression vectors in OptiMEM for 3-5 hours. The transfection mixture was removed and the cells supplemented with Ham
F-12 media for an overnight incubation at 37°C.
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C. Western blot for total cell protein expression. CHO-K1 cells were transfected as described
above. After an overnight incubation, cells were rinsed with PBS+ (phosphate-buffered saline
containing 0.5 mM Mg2+, 0.9 mM Ca2+), detached with trypsin-EDTA and lysed using a RIPA
buffer (radioimmunoprecipitation assay buffer: 1% NaDOC, 1% TX100, 0.1% SDS, 10 mM TrisCl pH 7.4) with a mammalian protease inhibitor cocktail (M250, Amresco). Cell lysates were
centrifuged at 14,000 g at 4°C for 5 minutes. The supernatants were collected, added to sample
buffer with sodium dodecyl sulphate (SDS) and 2-mercaptoethanol, and boiled for 5 min.
Samples were loaded on a 12% precast polyacrylamide gel (Bio-Rad) and separated by SDSPAGE.
Proteins were transferred to 0.2 µm nitrocellulose membrane (Bio-Rad) at 150V for 1.5
h. Blots were blocked with 5% dry milk for 30 minutes at room temperature (RT) or overnight at
4°C. Blots were then incubated for 2h at RT with anti-HSV1 gD PAb peptide 340-356 antibody
or anti-EBV gB PAb antibody diluted in PBS with 0.3% tween (PBS-T) and 5% milk. Blots were
washed three times (5 minutes/wash) with PBS-T and goat anti-rabbit-HRP was added at a
1:7,000 dilution in PBS-T with 5% milk for 1 hour, rocking at RT. After three PBS-T washes, the
membranes were developed using enhanced chemiluminescence (ECL) substrate (Pierce) and
detected with an HD2 imager (ProteinSimple).

D. Cell-based enzyme-linked immunosorbent assay (cELISA). To determine the protein
expression on the surface of the cells. CHO-K1 cells were seeded (6 x 104 cells/well) in a 96-well
plate and triplicate wells were transfected with 110 ng/well of DNA using 0.35 µL Lipofectamine
2000/well (50 µL/well, total volume). The cells were incubated overnight at 37°C. The wells
were blocked for 30 minutes at RT with PBS-BSA (PBS+ with 3% [wt/vol] bovine serum
albumin). Cells were incubated with R7 diluted 1:2,500 or CL55 diluted 1:10,000 in PBS-BSA
on ice for 1 hour. The wells were rinsed three times with PBS+ and fixed in PBS+ with 2%
formaldehyde and 0.2% glutaraldehyde. Cells were rinsed and incubated with goat anti-rabbit-
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HRP at 1:5,000 dilution or goat anti-mouse-HRP at 1:2,000 dilution for 1 hour at RT. Expression
was determined by adding TMB microwell peroxidase substrate (Fisher) and measuring the
absorbance at 670 nm on Biotek Cytation 3 Cell Imaging Multi-Mode Reader.

E. Western blot for proximity biotinylation. CHO-K1 cells seeded overnight in a 24 well plate
(3 x 105 cells/well) were transfected as described above. After the overnight transfection, the cells
were pulsed with 20 µM biotin at 37°C. Cells lysates were collected and subjected to SDSPAGE, as described above, using duplicate gels. Samples were transferred to nitrocellulose as
above and membranes were blocked with PBS with 1% BSA for 30 minutes at RT or overnight at
4°C. BSA was used to block the membranes because milk inhibits the biotin-streptavidin
interaction. One membrane was incubated with streptavidin-HRP in PBS-T with 1% BSA for 1h
and washed three times with PBS-T. The duplicate membrane was incubated for 2 hours at RT
with either EBV gB PAb (diluted 1: 1,000 in PBS-T with 1% BSA) or 12CA5 (diluted 1: 2,000)
in PBS-T with 1% BSA) to detect the HA-tagged AP constructs. This membrane was washed
and incubated with either goat anti-rabbit-HRP (1:10,000 dilution) or goat anti-mouse-HRP
(1:7,000 dilution) in PBS-T with 1% BSA. Both blots were developed using ECL as described
above. Then the duplicate blot was stripped using two 7 minute washes in a mild stripping buffer
(15g glycine, 1g SDS, 10 mLTween-20 per liter adjusted to pH 2.2) followed by two 10 minute
rinses in PBS and two 5 minutes rinses in Tris-buffered saline with 0.1 % Tween-20. Signal loss
was confirmed by imaging the blot using ECL. This blot then was re-probed for 2 hours at RT
using either anti-gD 340-356 PAb (diluted 1: 2,000 in PBS-T with 1% BSA) or anti-FLAG MAb
(diluted 1: 7,000 in PBS-T with 1% BSA) to detect the FLAG-tagged BirA constructs. The blot
then was washed, incubated with goat anti-mouse-HRP and developed as above.

F. Depletion of biotin from medium. Ham’s F12 supplemented with 10% FBS and 1%PS was
depleted of free biotin by adding of 50 µg/mL of streptavidin (New England Biolabs 721). CHO-
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K1 cells were transfected as described above, but the transfection mix was removed after 3-5
hours and biotin-depleted media was added for the overnight incubation.

G. Proximity biotinylation with immunoprecipitation. CHO-K1 cells were seeded in a 12
well plate (6 x 105 cells/well) and transfected as described with 440 ng of DNA/construct (880
ng/well). After an overnight incubation, the cells were pulsed with 20 µM biotin for 5 minutes at
37°C and cell lysates were collected as above using 400 µL/well of RIPA buffer. The lysates
were split, with 75 µL of each lysate reserved for immunoprecipitation (IP) (36). The rest of the
cell lysates were analyzed by SDS-PAGE and western blot as described above.
To IP the AP constructs, 5µL of 12CA5 MAb was added to 75µL of lysates for 2h at 4°C
on a rotator. 15µL of a 50% protein A/G+ bead slurry (Santa Cruz Biotechnology) was added for
1h at 4°C on the rotator. After pelleting at 14,000 rpm for 1 minute at 4°C, the beads were
washed with 1 mL RIPA buffer 5 times, with 30 seconds of centrifugation at 4°C after each wash.
SDS-sample buffer at 2X with 2-mercaptoethanol was added to each pellet of beads. The samples
were boiled for 5 minutes and centrifuged at 14,000g for 1 minute. The IP samples were
separated by SDS-PAGE, transferred to nitrocellulose, and probed with streptavidin-HRP as
described above.

H. Competition proximity biotinylation assay. CHO-K1 cells seeded overnight in a 24 well
plate (3 x 105 cells/well) were transfected with 450 ng/µL DNA per well, including 100 ng per
AP- or BirA-linked construct and 250 per competitor construct. Cells were transfected in OptiMEM (Gibco) medium using Lipofectamine 2000 (Invitrogen) according to the manufactures
directions. After 3-5 hours, the transfection mixture was removed and the cells were
supplemented with Ham’s F-12 media at 37°C. After an overnight incubation, the cells were
pulsed with 20 µM biotin at 37°C for 5 minutes. Cells lysates were collected and subjected to
SDS-PAGE, as described above, using duplicate gels. The western blots were performed as
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described above, with one blot probed using streptavidin-HRP and the other blot probed with
anti-HA antibody and then re-probed with anti-FLAG antibody.

I. Competition assay with gH. CHO-K1 cells seeded overnight in a 12 well plate (6 x 105
cells/well) were transfected with 880 ng DNA per well (340 ng per construct, 100 ng HSV1 gH,
100 ng HSV1 gL), as described above. After an overnight incubation, the cells were pulsed with
20 µM biotin at 37°C for 5 minutes. Western blots were performed using cell lysates as described
above, with one blot probed using streptavidin-HRP and another probed with anti-HA antibody
followed by stripping and reprobing using anti-FLAG antibody.

J. Syncytium formation assay. CHO-nectin1 cells were seeded (6 x 105 cells/well) overnight in
24-well plates and then transfected with plasmids encoding HSV1 gB (pPEP98), gH (pPEP100),
gL (pPEP101), and either gD (pPEP99), gD-BirA or gD-APm. Each well received 900 ng DNA
total, including 300 ng gB plasmid and 200 ng for each of the rest of the plasmids. The cells were
transfected in Opti-Mem (Gibco) medium for 3-5 hours using Lipofectamine 2000 (Invitrogen)
according to the manufactures directions. The transfection mixture was replaced with Ham F-12
supplemented with 10% FBS and PS and cells were incubated overnight at 37°C. Cells were
fixed with methanol, stained with Giemsa (GibcoBRL), rinsed with water, and scored for
syncytium formation by microscopy.

K. Densitometry. To quantify the western blot bands the backgrounds of the blot were subtracted
from the band. Densitometry values were determined using AlphaView Software from the
FluorChem HD2 imager from ProteinSimple. Values are provided under each blot.

	
  

18

	
  
III. Results

A. Positive and negative ProB controls. HSV and EBV entry glycoproproteins form multimers
and thus detection of proximity between monomers of a glycoprotein can be used a positive
control for the ProB assay. The entry glycoproteins of EBV cannot be substituted for those of
HSV and vice versa. Since glycoproteins from the two viruses do not functionally interact, they
are not expected to physically interact, and thus they provide a negative control for the ProB
assay. HSV1 gB and EBV gB share 29% identity and 43% similarity (7). Although the crystal
structures of HSV1 and EBV gB demonstrate a common fold for these homologous proteins, their
extensive sequence variations should preclude interaction of gB with heterotypic viral
glycoproteins (7, 29). EBV does not utilize a glycoprotein gD. When EBV enters B cells, it uses
gp42; however, gp42 is not required for entry into epithelial cells. There is no functional reason
that EBV gB should interact with HSV1 gD.
To validate ProB as a viable method to detect interactions between the HSV1
glycoproteins necessary for entry, ProB constructs were cloned for HSV1gD and EBV gB. The
cytoplasmic tails of these proteins were linked to either biotin ligase (BirA) or its target peptide
(AP or APm) (Fig. 3). APm is a 3 amino acid deletion, removing a tryptophan, histidine, glutamic
acid from the original AP, shown to reduce background signal since it has a lower affinity for
BirA (21). The BirA-linked constructs have a FLAG epitope tag, and AP- or APm-linked
constructs have a hemagglutinin (HA) epitope tag.

B. Expression of HSV1 and EBV constructs. To determine if HSV1 gD constructs were
expressed, plasmids encoding the constructs were transfected into CHO-K1 cells, and proteins
from total cell lysates were analyzed by western blot (Fig. 4A). The wildtype HSV1 gD, gD-AP,
and gD-APm migrated to 50 kDa, while gD-BirA migrated to 75 kDa (Fig. 4A). The proteins
were detected with a polyclonal antibody serum specific for HSV1 gD. HSV1 gD-BirA was
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Figure 3. Proximity biotinylation constructs. Schematic representation of HSV1 gD (A) and
EBV gB (B) constructs linked with the biotin ligase BirA or the target peptides AP and APm.
The BirA, AP, and APm were added to the cytoplasmic tails of the glycoproteins. The dark blue
and green boxes represent the transmembrane domains. BirA-linked constructs include a Cterminal FLAG epitope. AP- and APm-linked constructs include a C-terminal HA tag. HSV gDBirA is expected to migrate to 75 kDa while HSV gD-AP and –APm are expected to migrate to
50 kDa. EBV gB-BirA is expected to migrate to 200 kDa, and EBV gB-AP and –APm are
expected to migrate to 140 kDa.
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Figure 4. Expression of HSV1 constructs. (A) Western blot of HSV1 gD constructs. Total cell
lysates of CHO-K1 cells transfected with the gD constructs or empty vector were analyzed by SDSPAGE. Proteins were transferred to nitrocellulose and probed using a polyclonal antibody serum
specific for HSV1 gD. Size markers in kDa are indicated on the left. Densitometry values for the
bands (~75 kDa for lane 2, ~50 kDa doublet for lanes 3-5) are below the blot. (B) CELISA of HSV1
gD constructs. CHO-K1 cells were transfected with the gD constructs or empty vector and probed for
cell surface expression of gD using a polyclonal antibody serum. HRP-conjugated secondary
antibody was added followed by substrate. Absorbance at 670 nm was recorded as a measure of
expression.
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expressed at lower levels than wildtype gD. Cell surface expression of these gD proteins in CHOK1 cells was determined by cELISA (Cell-based Enzyme-Linked Immunosorbent Assay) using a
gD polyclonal antibody (Fig. 4B). All the HSV1 gD constructs were present on the cell surface,
suggesting that they were properly processed. gD-BirA was expressed on the cell surface at near
wild-type levels, whereas gD-AP and gD-APm were present on the surface at somewhat lower
levels.
The expression of the EBV gB constructs also was detected by western blotting of
transfected CHO-K1 cell lysates (Fig. 5A) and cELISA of transfected CHO-K1 cells (Fig. 5B).
Wild-type EBV gB is known to be poorly expressed at the cell surface, so two gB mutants
(gB767 and gB816) that were previously shown express at higher levels on the cell surface were
included as controls (24). gB767 and gB816 have cytoplasmic tail truncations that remove
putative endocytosis motifs. As expected, EBV gB-BirA migrated to 200 kDa, wildtype gB, gBAP, and gB-APm migrated to 140 kDa, and the truncated gB767 and gB816 migrated more
rapidly (Fig. 5A). The gB ProB constructs were expressed at near wild-type levels in the cell
lysates whereas the truncation mutants were expressed at lower levels. As previously reported
(24), wild-type gB expression on the surface was barely detectable (Fig. 5B). The ProB
constructs were also poorly expressed at similar levels on the cell surface. As expected, the gB
truncation mutants were expressed at higher levels on the cell surface. The increase in surface
expression for these mutants without a concurrent increase in total cell expression is consistent
with previous reports (24). Surface expression of the ProB mutants at near wild-type levels
suggests that the proteins are properly processed.

C. Initial ProB trial. In the initial trial of ProB, CHO-K1 cells were transfected with
combinations of HSV1 gD constructs, EBV gB constructs, and/or empty vector. Cells were
pulsed with 20 µM biotin for 15 minutes and lysed. Cell lysates were analyzed by western blots.
The levels of protein biotinylation were detected using streptavidin-HRP (Fig.6A).

	
  

22

	
  

Figure 5. Expression of EBV constructs. (A) Western blot of EBV gB constructs. Total cell
lysates of CHO-K1 cells transfected with gB constructs or empty vector were analyzed by SDSPAGE. gB767 and gB816 are mutant forms of gB that were previously shown to be expressed at
high levels on the cell surface. Proteins were transferred to nitrocellulose and probed with a
polyclonal antibody serum specific for EBV gB. Size markers in kDa are indicated on the left.
Densitometry values for the bands are below the blot. (B) CELISA of EBV gB constructs. CHOK1 cells were transfected with the gB constructs or empty vector and probed for cell surface
expression of gB using a polyclonal antibody serum. HRP-conjugated secondary antibody was
added followed by substrate. Absorbance at 670 nm was recorded as a measure of expression.
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Coexpression of the homotypic pair HSV1 gD-BirA and HSV1 gD-APm resulted in strong
biotinylation of the gD-APm target (~60 kDa, lane 3). Coexpression of the homotypic pair EBV
gB-BirA and EBV gB-APm also resulted in strong biotinylation of the gB-APm target (~140
kDa, lane 8). Thus, proximity was detected in the positive controls. Results were similar whether
the AP or APm constructs were used (data not shown). APm is shown instead of AP because it
has a reported lower affinity for BirA and resulted a reduction in non-specific bands (data not
shown).
Unexpectedly, coexpression of the heterotypic pairings also resulted in biotinylation of
the APm targets. Coexpression of HSV1 gD-BirA with EBV gB-APm resulted in biotinylation of
gB-APm (~140 kDa, lane 4); however, the biotinylation was weaker than that observed for
homotypic gB-BirA and gB-APm expression (lane 8). The other heterotypic combination (EBV
gB-BirA and HSV1 gD-APm) also showed a weak biotinylation of the gD-APm (~60 kDa, lane
9). The band migrating at ~60 kDa in lanes 4 and 8 is likely a degradation product of biotinylated
EBV gB-APm since it is only present in gB-APm containing samples.
gD-BirA, gD-APm, and wildtype gD expression was detected with a polyclonal antibody
specific for peptide 340-356 of HSV1 gD. Both the enzyme and the substrate gD constructs were
expressed but HSV1 gD-APm is expressed at a higher level compared to HSV1 gD-BirA (Fig.
6C). Expression of EBV gB-BirA, APm, and wildtype was detected with a polyclonal antibody
specific for EBV gB (Fig. 6B). Expression of both EBV gB-BirA and gB-APm is detected,
however EBV gB-BirA expression in the last two lanes is weak. Interpretation of the heterotypic
interaction between gB-BirA and gD-APm (lane 9) is complication by the poor detection of the
gB-BirA expression. Subsequent experiments determined that the antibody for EBV gB does not
detect gB as well as the antibody used for HSV1 gD, which could explain the lack of detection of
the EBV gB glycoproteins on the cell surface. To try to reduce the signal for the heterotypic
interaction, the exposure to biotin and amount of DNA transfected was reduced.
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Figure 6. Initial trial of proximity biotinylation. CHO-K1 cells were transfected overnight
with combinations of HSV1 gD constructs, EBV gB constructs, and/or empty vector. Each
sample was transfected with 660 ng DNA total, comprising 220 ng per construct. Cells were
pulsed with 20 µM biotin for 15 min and then lysed. Cell lysates were analyzed by SDS-PAGE
and proteins were transferred to nitrocellulose. Duplicate blots were generated and size markers
in kDa are indicated on the left. (A) Biotinylated proteins were detected by probing with
streptavidin-HRP. The arrowhead denotes biotinylated EBV gB and the asterisk denotes a
doublet band of biotinylated HSV1 gD. (B) EBV gB expression was detected by probing a
duplicate blot with polyclonal serum. (C) The blot from B was stripped and reprobed with
polyclonal serum to detect HSV1 gD expression. Densitometry values for the bands of interest
are below each blot. For A and C, the upper value represents the larger molecular weight species.
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D. ProB assay optimization with lower amounts of DNA, shorter biotin exposure. Since the
level of biotinylation was greater than expected in the heterotypic combinations, the amount of
DNA transfected was reduced and the cell exposure to biotin was shortened (Fig. 7). The amount
of DNA was reduced more than 2-fold from the previous experiment (to 300 ng DNA per well).
Cells were exposed to the same concentration of biotin (20 µM), but for 5 minutes rather than 15
minutes. The HSV1 gD homotypic combination showed a strong biotinylation signal (lane 3, ~60
kDa), as did the EBV gB homotypic combination (lane 7, ~140 kDa). The heterotypic pairing of
HSV1 gD-BirA and EBV gB-APm resulted in biotinylation of gB-APm (lane 4, ~140 kDa), but
quantification of this band is difficult due to the presence of a background band in all of the lanes
that migrates at the same molecular weight. This cellular biotinylated protein was present in the
previous experiment (Fig. 6), but at lower levels compared to gB. Reducing the amount of DNA
transfected complicated interpretation of the blot because the ratio of expression of gB to the
background band was reduced. A heterotypic interaction between EBV gB-BirA and HSV1 gDAPm is apparent (lane 8, ~60 kDa). A degradation product of biotinylated gB-APm is apparent
again in lanes 4 and 8 at ~60 kDa. The dots in lane 3 are an artifact, most likely streptavidin-HRP
precipitate that adhered to the blot. The gD and gB constructs EBV were expressed at levels
similar to the previous western blots (data not shown). The EBV polyclonal antibody still was not
detecting gB levels well. To better detect gB and gD constructs, a new set of antibodies was used
that allows direct comparison of the levels of BirA enzyme and APm substrate.

E. ProB assay optimization using the FLAG and HA epitopes. Since the EBV gB antibody did
not detect EBV gB well, antibodies specific for the FLAG and HA epitopes on the proteins were
tested. Using the epitope tags to detect the proteins also allowed better comparison of protein
levels, since both of the BirA enzymes constructs have FLAG tags, and both of the APm substrate
constructs have HA tags. Constructs were co-transfected in this experiment to determine the
expected expression levels of the glycoproteins when co-transfected in future experiments (Fig.
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Figure 7. Proximity biotinylation trial with less DNA and shorter biotin exposure. CHO-K1
cells were transfected overnight with combinations of HSV1 gD constructs, EBV gB constructs,
and/or empty vector. Each sample was transfected with 300 ng DNA total, comprising 100 ng
per construct. Cells were pulsed with 20 µM biotin for 5 min and then lysed. Cell lysates were
analyzed by SDS-PAGE and proteins were transferred to nitrocellulose. Biotinylated proteins
were detected by probing with streptavidin-HRP. The two halves of the blot are from the same
exposure. Size markers in kDa are indicated on the left. The arrowhead denotes biotinylated EBV
gB and the asterisk denotes a biotinylated HSV1 gD. Densitometry values for the bands of
interest are below each blot. The upper value represents the larger molecular weight species.
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Figure 8. Detection of constructs expression using HA and FLAG tags. Western blot of APm
and BirA constructs. Total cell lysates of CHO-K1 cells transfected with HSV1 gD constructs,
EBV gB constructs, and/or empty vector were analyzed by SDS-PAGE. Proteins were transferred
to nitrocellulose and probed with a monoclonal antibodies specific for the HA tag (A) or the
FLAG tag (B). Size markers in kDa are indicated on the left. The arrowhead denotes EBV gB
and the asterisks denote HSV1 gD. Densitometry values for the bands of interest are below each
blot. For A, the upper value represents the larger molecular weight species.
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8). EBV gB-APm was detected at ~140 kDa and HSV1 gD-APm was detected at ~60 kDa (Fig.
8A). EBV gB-BirA was detected at ~150 kDa and HSV1 gD-BirA was detected at ~75 kDa (Fig.
8B). Stronger signals were perceived with the anti-FLAG monoclonal antibody and the anti-HA
monoclonal antibody compared to the EBV gB antibody seen in previous blots. Cellular proteins
that react with the anti-HA antibody are present in all lanes and migrate to the same molecular
weight as gD as well as at ~75 kDa.
A ProB assay was performed as previously, using 375 ng DNA per well and the HA or
FLAG epitopes to assess protein expression levels (Fig. 9). Biotinylation is apparent in the
homotypic combinations for both HSV1 gD (lane 2) and EBV gB (lane 6). The heterotypic
combinations have weaker but detectable biotinylation signals (lanes 3 and 7). All of the APm
and BirA constructs were expressed, with the gB constructs again at higher levels than the gD
constructs again (Fig. 9B, 9C). The detection of the enzyme and substrate with the HA and FLAG
epitopes were useful for comparison of the enzyme levels (gB-BirA and gD-BirA) and substrate
levels (gB-APm and gD-APm).

F. ProB with depletion of free biotin. The cellular protein(s) that react with streptavidin-HRP
and migrate to ~140 kDa obscure observation of biotinylated gB-APm. These bands may result
from endogenous biotin being detected by the streptavidin-HRP. In attempt to decrease the
presence of these background biotinylated species, two sets of ProB samples were compared.
One set was treated as before (Fig. 10A) and for a second set, the media was depleted of free
endogenous biotin by the addition of streptavidin (Fig. 10B). For this second set, streptavidin
was maintained in the media after transfection for the duration of the overnight incubation prior
to the biotin pulse. CHO-K1 cells were transfected with 660 ng DNA per well total, including 220
ng per construct. As seen previously, the homotypic combinations yield strong biotinylation
signals (Fig. 10A, lanes 2 and 6). The heterotypic combination yields weaker biotinylation signals
than the homotypic interactions (Fig. 10A, lanes 3 and 7). Depletion of the free biotin did not
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Figure 9. Proximity biotinylation using HA and FLAG tags. CHO-K1 cells were transfected
overnight with combinations of HSV1 gD constructs, EBV gB constructs, and/or empty vector.
Each sample was transfected with 300 ng DNA total, comprising 150 ng per construct. Cells were
pulsed with 20 µM biotin for 5 min and then lysed. Cell lysates were analyzed by SDS-PAGE
and proteins were transferred to nitrocellulose. Size markers in kDa are indicated on the left. (A)
Biotinylated proteins were detected by probing with streptavidin-HRP. The arrowhead denotes
biotinylated EBV gB and the asterisks denote a doublet band of biotinylated HSV1 gD. (B) APm
was detected by probing a duplicate blot with an antibody specific for the HA tag. (C) The blot
from B was stripped and reprobed with an antibody specific for the FLAG tag, detecting BirA
expression. The arrowhead denotes EBV gB and the asterisks denote HSV1 gD. Densitometry
values for the bands of interest are below each blot. For A, the upper value represents the larger
molecular weight species.
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Figure 10. Proximity biotinylation after biotin-depletion of the medium. Duplicate sets of
CHO-K1 cells were transfected with combinations of HSV1 gD constructs, EBV gB constructs,
and/or empty vector. Each sample was transfected with 660 ng DNA total, comprising 220 ng
per construct. One set of samples was treated as in Fig. 5 (A). The medium for the other set (B)
was supplemented with 50 µg/mL streptavidin to bind endogenous biotin. After an overnight
incubation, all cells were pulsed with 20 µM biotin for 5 min and then lysed. Cell lysates were
analyzed by SDS-PAGE and proteins were transferred to nitrocellulose. Biotinylated proteins
were detected by probing with streptavidin-HRP. The arrowhead denotes biotinylated EBV gB
and the asterisks denote a biotinylated HSV1 gD. Densitometry values for the bands of interest
are below each blot. The upper value represents the larger molecular weight species.
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affect the results (Fig. 10B) and did not decrease the signal from the background cellular protein
migrating at the same size as gB-APm. The biotinylated species is not impacted by depletion of
the free biotin in the media.

G. ProB with immunoprecipitation (36). To reduce the impact of the non-specific bands in the
western blots, the APm constructs were immunoprecipitated prior to loading the gels. The ProB
was performed and cell lysates were collected as previously. Then the APm constructs were
immunoprecipitated from the lysates using an antibody specific for the HA tag and beads
covalently-conjugated to protein A/G. Samples were reordered on the gel for easier comparison
of homotypic and heterotypic combinations. The IP eliminated the biotinylated cellular species
that previously obscured the gB-APm band. As before, both homotypic and heterotypic
interactions are apparent. Biotinylation of gD-APm is similar when it is coexpressed with either
homotypic gD-BirA or heterotypic gB-BirA (Fig. 11A, lanes 1 and 2). Given than gB-BirA is
expressed at a greater level than gD-BirA (Fig. 11C), this may indicate that biotinylation of the
homotypic combination is more specific than the heterotypic combination. Biotinylation of gBAPm is greater when it is coexpressed with the homotypic gB-BirA rather than the heterotypic
gD-BirA (Fig. 11A, lanes 4 and 5), however this results may be influenced by the fact that gDBirA is expressed at lower levels than gB-BirA (Fig. 11C).

H. gD construct function in fusion. The HSV1 gD constructs tagged with BirA and APm were
tested for their ability to mediate cell-cell fusion. CHO-nectin-1 cells were used since this cell
type expresses nectin-1, a herpesvirus receptor expressed on neurons. CHO-nectin-1 cells
transfected with wildtype HSV1 gB, gD, gH, and gL formed large syncytia (Fig. 12). When the
fusion protein gB was excluded from the transfection, cells did not form syncytia. When cells
were transfected with plasmids encoding gB, gH, gL and either gD-APm or gD-BirA, many large
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Figure 11. Proximity biotinylation with immunoprecipitation. CHO-K1 cells were transfected
overnight with combinations of HSV1 gD constructs, EBV gB constructs, and/or empty vector.
Each sample was transfected with 880 ng DNA total, comprising 440 ng per construct. Cells
were pulsed with 20 µM biotin for 5 min and then lysed. Lysates were divided for
immunoprecipitation (A) or direct loading onto the gel (B and C). (A) The APm constructs were
immunoprecipitated from the lysates using an antibody specific for the HA epitope tag and
protein A/G beads. Biotinylated proteins were detected by probing with streptavidin-HRP. (B)
APm was detected by probing a duplicate blot with an antibody specific for the HA tag. (C) The
blot from B was stripped and reprobed with an antibody specific for the FLAG tag, detecting
BirA expression. The arrowhead denotes EBV gB and the asterisks denote HSV1 gD.
Densitometry values for the bands of interest are below each blot. For A, the upper value
represents the larger molecular weight species.
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Figure 12. Syncytium formation with gD constructs BirA and APm. CHO-nectin-1 cells
were transfected with plasmids encoding HSV1 glycoproteins or gD constructs, and/or empty
vector. The results shown are representative of 3 replicates. The images were taken 24h post
transfection. Arrows indicate syncytia.
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syncytia formed. The results indicated that gD-APm and gD-BirA are functional proteins, further
supporting that they are properly folded in the cell.

I. ProB competition assay. To examine specificity of the ProB assay and address whether the
affinity of BirA for APm contributes to the biotinylation signal, wildtype protein was added in
attempt to outcompete the heterotypic interaction. If the interactions that yield biotinylation are
driven by attractions between the glycoprotein ectodomains, excess wild-type protein should be
able to compete for the binding and decrease the biotinylation signal. In contrast, if the
interactions that yield biotinylation are driven by an inherent attraction between BirA and APm,
the addition of excess wildtype gD or gB should not affect the level of APm biotinylation.
For the heterotypic gD-BirA and gB-APm combination, coexpression of wildtype EBV
gB resulted in a slight reduction in gB-APm biotinylation (Fig. 13, lane 5 and 6). This reduction
suggested that the heterotypic gD-BirA interaction with gB-APm might result from interactions
with the gB ectodomain rather than from an inherent affinity between BirA and APm, however
this competition was not consistently detected. When the heterotypic combination was reversed
(gB-BirA coexpressed with gD-APm), coexpression of wildtype gD did not inhibit biotinylation
(lanes 3 and 4). Furthermore, the level of biotinylation for the homotypic gB-BirA and gB-APm
combination was not affected by the addition of wildtype gB (lane 7 and 8). The crystal
structure of the gB ectodomain (29) demonstrates that the gB ectodomin trimerizes, so wildtype
gB was expected to inhibit the interaction between gB-BirA and gB-APm. The inability to detect
competition by wild-type gB suggests that the inherent affinity between BirA and APm may
contribute to gB-APm biotinylation. The gD homotypic combination failed to show high levels
of biotinylation (lanes 9 and 10). This may be due to poor expression of gD-BirA. When the
BirA blot was stripped and re-probed with the anti-gD polyclonal antibody, no gD-BirA was
detected. It was expected to migrate to 75 kDa. Subsequent experiments failed to show clear
competition when the wildtype protein was coexpressed with corresponding combinations.
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J. ProB HSV1 gH/gL competition assay. On the HSV1 virion, gB and gD exist in combination
with gH/gL. To examine whether gH/gL influences the HSV1 gD-EBV gB interaction, HSV
gH/gL was added to the ProB assay. This assay is an alteration of the competition assay above.
Instead of using wildtype gD or gB to compete the interaction, HSV1 gH and gL were
coexpressed with the BirA and APm constructs. In one experiment, coexpression of the gH/gL
complex decreased biotinylation for the heterotypic combination of gB-BirA and gD-APm (Fig.
14, lanes 3 and 4). In the same experiment, coexpression of gH/gL did not affect homotypic
biotinylation of gD-APm by gD-BirA (lanes 1 and 2). The levels of APm biotinylation were
similar with or without gH/gL coexpression. Expression of the BirA constructs was unable to be
detected in that experiment and the results were not reproducible.
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Figure 13. Competition proximity biotinylation assay. CHO-K1 cells were transfected
overnight with combinations of HSV1 gD constructs, EBV gB constructs, and either empty
vector or wildtype proteins. Each sample was transfected with 450 ng DNA total, comprising
100 ng per construct or 250 ng per competitor. Cells were pulsed with 20 µM biotin for 5 min
and then lysed. Cell lysates were analyzed by SDS-PAGE and proteins were transferred to
nitrocellulose. (A) Biotinylated proteins were detected by probing with streptavidin-HRP. (B) A
blot detecting BirA expression using an antibody specific for the FLAG tag. (C) HSV1 gD
expression using a polyclonal antibody serum specific for HSV1 gD. Size markers in kDa are
indicated on the left. The arrowhead denotes biotinylated EBV gB and the asterisks denote a
biotinylated HSV1 gD. Densitometry values for the bands of interest are below each blot. For A,
the upper value represents the larger molecular weight species.
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Figure 14. Competition proximity biotinylation assay with HSV1 gH/gL. CHO-K1 cells were
transfected overnight with combinations of HSV1 gD constructs, EBV gB constructs, and either
empty vector or HSV1 gH/gL. Each sample was transfected with 880 ng DNA total, comprising
340 ng per construct or 100 ng for gH and gL. Cells were pulsed with 20 µM biotin for 5 min
and then lysed. Cell lysates were analyzed by SDS-PAGE and proteins were transferred to
nitrocellulose. (A) Biotinylated proteins were detected by probing with streptavidin-HRP. (B) A
blot detecting APm expression using an antibody specific for the HA tag. Size markers in kDa are
indicated on the left. The asterisk denotes a biotinylated HSV1 gD. Densitometry values for the
bands of interest are below each blot. For A, the upper value represents the larger molecular
weight species.
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IV. Discussion
The HSV1 gD constructs with BirA and APm linked to the cytoplasmic tails were
expressed, as demonstrated by western blot and CELISA (Fig. 4). Total cell protein expression of
gD-BirA expressed was reduced compared to wild-type gD, but cell surface expression was at
wild-type levels, suggesting that the mature protein is properly folded. The double banding
pattern apparent in the western blot for both wildtype and mutant gD constructs are likely due to
different glycosylation of this glycoprotein. The syncytia assay confirms the proper folding of
these gD ProB constructs, since they are functional in fusion (Fig. 12).
The EBV gB constructs with BirA and APm linked to the cytoplasmic tails also were
expressed as detected by western blotting (Fig. 5). As seen previously, detection of wild-type
EBV on the cell surface is difficult. The gB ProB constructs were detected on the cell surface at
the same low levels as wild-type gB. The EBV gB tail mutants (EBV gB767 and gB816) that are
known to be expressed at higher levels on the surface of the cell were detected at higher levels by
cELISA. The tail mutants do not show higher levels of overall expression in the western blot,
suggesting that these proteins localize preferentially to the cell surface. The tail mutants lack
internalization signals present in wildtype gB. These results suggest that the gB-BirA and gBAPm constructs exhibit wild-type levels of internalization. Overall, the gB constructs are
expressed at similar levels to wild-type gB.
The initial ProB trial showed biotinylation in both homotypic combinations (Fig. 6). The
gB homotypic biotinylation was greater than the HSV homotypic biotinylation. Both of the
heterotypic combinations also demonstrated biotinylation. Since these transmembrane
glycoproteins are tethered to a membrane, they are in close proximity with one another. This
proximity may facilitate random collisions that are sufficient to allow for the biotinylation of the
AP tag without specific protein-protein binding. Optimizations of the ProB assay conditions are
required to differentiate between a specific versus random interaction.
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When the amount of DNA and the biotin exposure time were reduced, the homotypic
interactions were harder to detect (Fig. 7). Since biotinylation was still seen, the shorter biotin
exposure time was sufficient for biotinylation. The protein expression after transfection using 100
ng per construct was too low for reliable detection in this ProB assay.
The HSV gD and EBV gB polyclonal antibodies did not detect the glycoproteins
effectively. The ProB constructs were designed with FLAG and HA epitopes and antibodies
specific for those tags gave enhanced detection of the proteins (Fig. 8). In addition, use of these
epitope tags allowed direct comparison of the levels of gB-BirA versus gD-BirA.
Using the epitope tags to compare enzyme levels during the ProB assay provided a
clearer picture. The substrate constructs (APm) were expressed at similar levels, but the enzyme
constructs (BirA) were not expressed at similar levels (Figs. 8, 9, 11). gD-BirA is expressed at a
lower level than gB-BirA and this complicates the interpretation of the results. Specifically,
comparing the gB homotypic interaction with the heterotypic interaction between gD-BirA and
gB-APm is difficult, since gD-BirA is expressed at lower levels than gB-BirA. The weaker
biotinylation seen with the heterotypic combination (Fig.11) could result simply from the lower
levels of enzyme expressed. This result cannot be interpreted to indicate that the homotypic
interaction is stronger than the heterotypic interaction.
A nonspecific band that migrates at the same molecular weight as gB-APm was apparent
on many of the western blots probed with streptavidin-HRP. This signal is from endogenous
biotinylated proteins, since it is present in samples that did not receive BirA. When the media was
depleted of free biotin by the addition of streptavidin, the nonspecific bands remained, indicating
that depleting endogenous biotin overnight was insufficient to eliminate endogenous biotinylation
(Fig. 10).
To eliminate this confounding nonspecific band, an antibody specific for the HA tag on
APm constructs was used to immunoprecipitate these proteins. The IP blot still shows a
nonspecific band at a molecular weight similar to gD-APm, but the band that overlapped the gB-

	
  

40

	
  
APm was successfully lost in the immunoprecipitation (Fig. 11). As seen in the previous ProB
trials, both of the homotypic combinations showed strong biotinylation, however the heterotypic
combinations also showed biotinylation. Interpretation of the specificity of the interaction
requires consideration of the expression levels of the constructs. The gD-APm and gB-APm
constructs are expressed at similar levels, so the effect of different APm concentrations in the
samples is minimized. In contrast, gB-BirA is expressed at greater levels than gD-BirA (up to
two-fold greater in some cases). Given that BirA is an enzyme, capable of biotinylating several
APm substrates, difference in BirA construct expression levels may be amplified (Fig. 15).
The homotypic combination of gD-BirA and gD-APm (Fig. 11, lane 1) results in
biotinylation levels similar to the heterotypic combination of gB-BirA and gD-APm (Fig. 11, lane
2). Since gD-BirA is expressed at lower levels than gB-BirA, this result may indicate that this
homotypic gD interaction is stronger than the heterotypic interaction (Fig. 15). In contrast,
although the homotypic combination of gB-BirA and gB-APm (Fig. 11, lane 4) results in over
two-fold greater levels of biotinylation than the heterotypic combination of gD-BirA and gBAPm (Fig. 11, lane 5), the lower expression of the gD-BirA may account for this difference.
The competition assay with HSV1 gH/gL showed that gH/gL may outcompete the
heterotypic interaction between HSV1 gD-APm and EBV gB-BirA (Fig. 14). A slight decrease is
seen in the heterotypic interaction with gH/gL compared to the heterotypic interaction without
(lane 3 and 4). This decrease was difficult to reproduce and more experiments need to be
performed to replicate these results.

A. Proximity biotinylation potential. ProB has been used previously to detect cytosolic protein
interactions, however its use as a method to detect transmembrane protein interactions may be
limited. The ProB assay was used successfully to study with the intracellular protein-protein
interactions FKBP or FK506 and FKBP-rapamycin binding (FRB) protein, which is regulated by
rapamycin (21). Transmembrane proteins have restricted mobility while in the membrane. This
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Figure 15. Depiction of the effect of enzyme concentration on biotinylation. (A,B)
Homotypic combinations. (C, D) Heterotypic combinations. (A and C) gD-BirA and gB-BirA
catalyze similar levels of biotinylation when coexpressed with gD-APm, however gD-BirA is
expressed at a lower level than gB-BirA. This may suggest that gD-BirA interacts more
frequently with the substrate gD-APm than does gB-BirA. (B and D) gB-APm is biotinylated to
a greater extent when coexpressed with homotypic gB-BirA rather than heterotypic gD-BirA,
however gB-BirA is expressed at a higher level than gD-BirA. This enhanced expression of gBBirA may contribute to its ability to biotinylate gB-APm to a greater degree.
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may contribute to unexpected non-specific interactions between the HSV1 gD and EBV gB
proteins.
As discussed, the expression level of the BirA-linked construct is critical for
interpretation of the data. In addition, the functionality of the BirA enzyme linked to each
construct may differ. ProB is ideal for proteins with flexibility in their structures or proteins that
are able to function with an altered shape. The spacing from the membrane of a BirA and APm
pair may affect the frequency of biotinylation.
ProB has the potential to be a useful method to study protein interactions due to the use
of an enzyme-substrate pair instead of the use of a fluorophore. The target substrate is a small tag,
which has a limited ability to affect the function of the protein whereas the BirA enzyme is about
20 kDa. The detection of the interaction is determined via western blot, making it easier to
quantify than microscopy. The major advantage of ProB is the covalent linking of biotin to the
AP tag, permanently tagging the protein.
This thesis project was to establish and optimize a protocol for proximity biotinylation.
The number of cells used, the antibody dilutions, the selection of antibodies, the amounts of
DNA, biotin exposure, endogenous biotin depletion, and immunopreciptation conditions were
optimized for this assay.

B. Future work. The interactions between the HSV1 glycoproteins are an active area of
research. Further optimization of the ProB assay to reduce detection of nonspecific interaction
may be possible.
HSV1 gD and EBV gB were not expected to physically interact because EBV gB and
HSV1 gB cannot functionally replace one another. In addition, they have low sequence
homology (~30%) and EBV does not encode a gD homolog. These facts do not preclude the
possibility that HSV1 gD and EBV gB interact in a specific but non-functional manner. An
alternative negative control could be used to optimize the ProB assay, such as the fusion
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glycoprotein F from the paramyxovirus parainfluenza virus 5 (PIV5). F protein is a fusion protein
on the surface that PIV5 that triggers membrane fusion. PIV5 F has no sequence homology to
HSV1 proteins. This is reasonable negative control since it is a transmembrane protein that forms
a trimer and thus could be used to examine both homotypic and heterotypic interactions.
The ProB competition assay results with wildtype EBV gB and HSV1 gD, as well as
HSV1 gH/gL, should be repeated to determine if the results are reproducible. Examination of the
interaction of HSV1 gH/gL with HSV1 gD and gB can be examined once the ProB specificity
concerns are addressed.
BirA and APm interactions can also be visualized through fluorescent microscopy. The
procedure is similar except the cells are not lysed but fixed and then stained with streptavidin
conjugated to AlexaFluor 568 or another fluorescent molecule. The media depletion of biotin can
reduce background biotin signal. Fluorescent microscopy analysis of the HSV1 gD and EBV gB
constructs can be beneficial in characterizing if any nonspecific interactions are happening during
processing in the endoplasmic reticulum instead of interacting on the cell surface.

C. Other protein-protein interaction methods. Further development in protein interaction
methods for herpesvirus proteins is necessary to characterize the interaction of the glycoproteins
for entry.
Proximity utilizing biotinylation and mass spectrometry (PUB-MS) employs the same
enzyme- substrate method using biotin ligase (BirA) and biotin-acceptor tag (AP). The
interactions can be monitored by western or mass spectrometry. The researchers used a strong
CMV promoter or a weaker MoMuLV enhancer to have AP in excess over BirA (40). Cloning
these herpesvirus proteins into plasmids with different promoters may help optimize the positive
and negative controls for the ProB assay.
Another method related to ProB is called ID-PRIME. This assay takes advantage of the
enzyme E. coli lipoic acid ligase, which catalyzes the covalent ligation of a coumarin fluorophore
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onto a peptide recognition sequence, LAP1 (62). Only when the proteins labeled with either the
ligase or LAP1 interact is the LAP1 labeled with coumarin, a blue fluorophore. Coumarin
labeling in the absence of the interaction is low. The enzyme was created in such a way that when
the interaction is present the labeling is maximally fast, but when the interaction is not present the
labeling is undetectably slow (62). The issue with this method is that some endogenous proteins
are lipoylated, arising to the same problem as endogenous biotinylation with ProB (62). Other
protein-protein interactions will not work for low affinity, transient interactions that occur with
the entry glycoproteins.

	
  

45

	
  
V. Appendix

Cloning BirA and APm onto the cytoplasmic tails of HSV1 gB, HSV1 gH, and PIV5 F. The
cloning strategy was designed using four-primer PCR. In this method, one primer pair is used to
amplify the 5’ fragment of a construct and a second primer pair is used to amplify the 3’ fragment
of a construct. The 3’ primer of the first PCR and the 5’ primer of the second PCR are designed
to have sequence overlap. Thus, the product of the first PCR will base-pair with the product of
the second PCR. The 5’ primer of the first PCR and the 3’ primer of the second PCR can then be
used to amplify the full-length construct. Incorporation of restriction sites into the 5’ and 3’
primer used in the second round of PCR allows the fragment to be ligated into an expression
vector. A benefit to the four-primer PCR approach is that the two halves of the construct can be
joined precisely, without any additional residues being added, such as those encoded by
restriction site sequences.
The primers were designed so that the BirA and APm fragments would be amplified
without any glycoprotein sequence included, so that these PCR products could be use to add BirA
or APm to any of the glycoproteins. The 3’ primer for amplifying BirA included a FLAG epitope
and the 3’ primer for amplifying APm included an HA epitope.
Primers also were designed to clone each glycoprotein in combination with BirA and
APm. The 5’ primer used to amplify the glycoproteins was the same, regardless of whether the
BirA or APm was to be added. The 3’ primers included sequence from the glycoprotein and
either BirA or APm. This 3’ primer is the primer that includes the sequence overlap required for
this four-primer PCR method. Plasmids pPEP100 (pCAGGs-gH), pSG5-EBVgB, and pCAGGsW3AF (PIV5 F protein), and pECFP-N1-BirA-neurexin were used as templates for
amplifications. The sequence of APm is short enough to be entirely encoded in the primer.
To amplify the 5’ fragment of the HSV1 gH-BirA construct, a 5’ primer (rSC22) and a 3’
primer (rSC25b) amplified gH with a 3’ end complimentary to BirA. To amplify the 5’fragment
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gH-APm, the same 5’ primer was used in combination with a 3’ primer (PCR28b) to amplify gH
with a 3’ end complementary to APm.
To amplify HSV1 gB-BirA, the 5’ primer rSC89 was used in addition to the 3’ primer
rSC25b. To amplify HSV1 gB-APm, the 5’ primer rSC18 was used with the 3’ primer rSC28b.
To amplify the 5’ fragments of the PIV5 F constructs, a 5’primer (rSC90) was used in
combination with a 3’ primer including F sequence and either BirA (rSC25c) or APm . (rSC28c)
sequence.
To amplify the 3’ BirA fragment, the 5’ primer (rSC63) was used in combination with a
3’ primer with the restriction enzyme site for BglII (rSC25b) or EcoRI (rSC25c). To amplify the
3’ APm fragment, the 5’ primer (rSC64) was used in combination with a 3’ primer with the
restriction enzyme site for BglII (rSC28b) or EcoRI (rSC28c).
The full-length constructs were amplified using the products of these PCRs and the
appropriate primer combinations, from the primers listed above. The primers used in this cloning
had varied length, by necessity, and were used in more than one PCR, thus optimization of the
PCR conditions was required. The viral glycoproteins have are GC-rich and thus optimization
was extensive, including temperature gradient PCR to determine optimal annealing temperatures
and the use of different polymerases.
The amplified full-length constructs were digested and ligated into the vector pSG5. This
vector has only three restriction sites in the multiple cloning site, so directional cloning was not
possible. The ligations were transformed into competent cells and the proper orientation of the
fragment was confirmed either by diagnostic restriction digest of DNA isolated from a
transformant by miniprep or by PCR amplification directly from an isolated colony.
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Table 1. Primer name and corresponding sequences for HSV1 gB, gH, and PIV5 F protein.

	
  

Primer
name

Gene/Plasmid

Sequence 5’ to 3’

rSC18

5’ EcoRIHSV1 gB

CGGAATTCACCATGCACCAGGGCGCCCCCTC

rSC22

5’ BglII-HSV1
gB

CGAGATCTACCATGGGGAATGGTTTATGGTT

rSC25b

RC3’ BirAFLAG-BglII

GCAGATCTCTACTTGTCGTCGTCGTCCTTGTAGTCACCTCCTTT
TTCTGCACTACGCAGG

rSC25c

RC3’ BirAFLAG-EcoRI

GCGAATTCTACTTGTCGTCGTCGTCCTTGTAGTCACCTCCTTTT
TCTGCACTACGCAGGG

rSC28b

RC3’ APmutFLAG-BglII

GCAGATCTCTAGAACTCGCCCTCGATCTTCTGGGCCTCGAAG
ATATCGTTCAGGCCGCCT

rSC28c

RC3’ APmutHA-EcoRI

GCGAATTCTAGAACTCGCCCTCGATCTTCTGGGCCTCGAAGA
TATCGTTCAGGCCGCCTC

rSC57

RC3’ HSV gBBirA

GGCACGGTGTTATCCTTCATCAGGTCGTCCTCGTCGGCGT

rSC58

RC3’ HSV gBAP

TCGGGCACGTCGTAGGGGTACAGGTCGTCCTCGTCGGCGT

rSC61

RC3’ HSV gHBirA

GGCACGGTGTTATCCTTCATTTCGCGTCTCCAAAAAAACG

rSC62

RC3’ HSV gHAP

TCGGGCACGTCGTAGGGGTATTCGCGTCTCCAAAAAAACG

rSC63

5’ BirA

ATGAAGGATAACACCGTGCC

rSC64

5’ HA-AP

TACCCCTACGACGTGCCCGACTACGCCAGCCTGGGAGGCGGC
CTGAACGATA

rSC89

5’ EcoRI-KOS
gB

GCGGAATTCACCATGCACCAGGGTGCACCCTCGT

rSC90

5’ EcoRI- PIV5
F

GCGGAATTCACCATGGGTACTATAATTCAATTTC

rSC91

RC3’ PIV5 FBirA

GGCACGGTGTTATCCTTCATTTTATGATAAACAAAATTCT

rSC92

RC3’ PIV5 FAP

TCGGGCACGTCGTAGGGGTATTTATGATAAACAAAATTCT
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Table 2. Optimal PCR conditions to amplify 5’ and 3’ fragments
Cycle 30X
Fragment

Enzyme

Template

Primers

Initial
Den.

PCR1d
(5’ BirA,
BglII)
pg 2-3

Vent

pECFPN1-BirAneurexin

rSC63,
rSC25b

98C,
60s

98C, 30s

66.5C,
60s

72C, 2:40

72C, 5
min

PCR5
(5’ gH,
BirA)
pg 1

Vent

pEP100
(pCAGGSgH)

rSC22,
rSC61

98C,
60s

98C, 30s

52C, 60s

72C, 2:40

72C, 5
min

PCR6
(5’ gH,
APm)
pg 1

Vent

pEP100
(pCAGGSgH)

rSC22,
rSC62

98C,
60s

98C, 30s

52C, 60s

72C, 2:40

72C, 5
min

PCR3
(5’ AP,
BglII)
pg 1

Vent

N/A

rSC64,
rSC28b

98C,
60s

98C, 30s

52C, 60s

72C, 2:40

72C, 5
min

PCR9
(5’ PIV5,
BirA)
pg 1

Vent

pCAGGSW3AF

rSC90,
rSC91

98C,
60s

98C, 30s

52C, 60s

72C, 2:40

72C, 5
min

PCR2e
(5’ BirA,
BglII)
pg 3

Vent

pECFPN1-BirAneurexin

rSC63,
rSC25b

98C,
60s

98C, 30s

47C, 60s

72C, 60s

72C, 5
min

PCR10
(5’ PIV5,
APm)
pg 1

Vent

pCAGGSW3AF

rSC90,
rSC92

98C,
60s

98C, 30s

52C, 60s

72C, 2:40

72C, 5
min

PCR4
(5’ AP,
EcoRI)
pg 1

Vent

N/A

rSC64,
rSC28c

98C,
60s

98C, 30s

52C, 60s

72C, 2:40

72C, 5
min

PCR7e
(5’ gB,
BirA
pg 23

Q5, GC
enhancer

pCAGGSHSV1-gB

rSC89,
rSC57

98C,
30s

98C, 10s

71C, 30s

72C, 1:45

72C, 2
min

PCR8n
(5’ gB,
AP)
pg 26

Q5, GC
enhancer

pCAGGSHSV-gB

rSC18,
rSC58

98C,
30s

98C, 10s

70C, 30s

72C, 2:15

72C, 2
min
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Anneal.

Extension

Final
Ext.

	
  

Table 3. Optimal PCR conditions to amplify fragments of glycoprotein with tag
Cycle 30X
Fragment

Enzyme

Temp
late

Primers

Initial
Den.

Denature

Anneal.

Extension

Final
Ext.

PCR11b
(gH-BirA)
pg 33

Vent

5, 1d

rSC22,
rSC25b

98C 1m

98C, 30s

54C, 1m

72C, 4m

72C, 5m

PCR12d
(gH-APm)
pg 34

Vent

6, 3

rSC22,
rSC28b

98C 1m

98C, 30s

57C, 1m

72C, 4m

72C, 5m

PCR13e
(F-BirA)
pg 41

Q5, no
enhancer

9, 2e

rSC90,
rSC25c

98C 1m

98C, 30s

70C, 3m

72, 1:40m

72C, 2m

PCR14 (FAPm) pg 4

Vent

10, 4

rSC90,
rSC28c

98C, 1m

98C, 30s

52C, 1m

72C, 4m

72, 5m

PCR15k
(gB-BirA)
pg 26

Q5, with
enhancer

7e, 1d

rSC89,
rSC25b

98C, 30s

98C, 10s

70C, 30s

72C, 2:15

72C, 2m

PCR16j
(gB-APm)
pg 27

Q5, no
enhancer

8n, 3

rSC18,
rSC28b

98C, 30s

98C, 10s

71C, 30s

72C, 2:15

72C, 5m
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Table 4. Confirmation of ligation of the PCR fragments into pSG5 vector.
Fragment

Lab
Notebook
Page

Restriction
Enzyme(s)

Expected
product

Date

Agarose Gel
L

PCR11b
(gH-BirA)

PCR12d
(gH-APm)
Colony
screen

40

XbaI

1292

2.5 kb

L

1

47

3

2

3
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(F-BirA)
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2
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PCR14 (FAPm)

31

BglII

4933,
463, 361

1/7/14

** This is the lane with the correct insert.
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NotI, BglII
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